Skip to main content
Erschienen in: International Ophthalmology 2/2014

01.04.2014 | Original Paper

Topical glaucoma therapy cost in Mexico

verfasst von: Gabriel Lazcano-Gomez, Alejandra Hernandez-Oteyza, María José Iriarte-Barbosa, Carlos Hernandez-Garciadiego

Erschienen in: International Ophthalmology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Glaucoma is an important cause of irreversible blindness that represents a significant economic burden; most direct costs of glaucoma are drug-related. We calculated the annual cost of some of the most commonly prescribed glaucoma medications in Mexico, according to their average wholesale price (AWP) and dose regimen. Annual costs ranged from USD4.97 for Imot 15 ml (timolol 0.5 %; Laboratorios Sophia) to USD675.39 for Alphagan 5 ml (brimonidine 0.2 %; Allergan, Inc.). β-Blockers were the least expensive glaucoma medications (range USD20.44–55.44). Alphagan 5 ml was 250 % more expensive than other selective α2-agonists. Of the carbonic anhydrase inhibitors, dorzolamide 2 % was less expensive than brinzolamide 1 % (USD326.91 vs. USD418.96). The annual cost for prostaglandin analogs ranged from USD235.58 for bimatoprost 0.03 % to USD337.78 for latanoprost 0.005 %. Some fixed combinations were less expensive than separate combinations. The average annual cost for all treatments increased by 27.87 ± 10.09 % between 2009 and 2012. Annual glaucoma therapy cost seems to be lower in Mexico than in other countries, due to a lower AWP, especially for some medications made by Mexican laboratories.
Literatur
2.
3.
Zurück zum Zitat Broman AT, Muñoz B, Rodriguez J, Sanchez R, Quigley HA, Klein R et al (2002) The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER. Invest Ophthalmol Vis Sci 43(11):3393–3398PubMed Broman AT, Muñoz B, Rodriguez J, Sanchez R, Quigley HA, Klein R et al (2002) The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER. Invest Ophthalmol Vis Sci 43(11):3393–3398PubMed
4.
5.
Zurück zum Zitat McKean-Cowdin R, Wang Y, Wu J et al (2008) Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology 115(6):941–948PubMedCrossRef McKean-Cowdin R, Wang Y, Wu J et al (2008) Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology 115(6):941–948PubMedCrossRef
6.
Zurück zum Zitat Rein DB, Wittenborn JS, Lee PP et al (2009) The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology 116:823–833PubMedCrossRef Rein DB, Wittenborn JS, Lee PP et al (2009) The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology 116:823–833PubMedCrossRef
7.
Zurück zum Zitat Rein DB, Zhang P, Wirth KE et al (2006) The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 124(12):1754–1760PubMedCrossRef Rein DB, Zhang P, Wirth KE et al (2006) The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 124(12):1754–1760PubMedCrossRef
8.
Zurück zum Zitat Lee PP, Walt JG, Doyle JJ et al (2006) A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 124(1):12–19PubMedCrossRef Lee PP, Walt JG, Doyle JJ et al (2006) A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 124(1):12–19PubMedCrossRef
9.
Zurück zum Zitat Traverso CE, Walt JG, Kelly SP et al (2005) Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 89(1):1245–1249PubMedCentralPubMedCrossRef Traverso CE, Walt JG, Kelly SP et al (2005) Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 89(1):1245–1249PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Gieser DK, Tracy Williams R, O’Connell W, Pasquale LR, Rosenthal BP, Walt JG et al (2006) Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study. J Glaucoma 15(5):419–425PubMedCrossRef Gieser DK, Tracy Williams R, O’Connell W, Pasquale LR, Rosenthal BP, Walt JG et al (2006) Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study. J Glaucoma 15(5):419–425PubMedCrossRef
11.
Zurück zum Zitat Olsen J, Berdeaux G, Skov J (2013) Glaucoma costs in Denmark in treatment naive patients. Acta Ophthalmol 91(1):25–31PubMedCrossRef Olsen J, Berdeaux G, Skov J (2013) Glaucoma costs in Denmark in treatment naive patients. Acta Ophthalmol 91(1):25–31PubMedCrossRef
12.
Zurück zum Zitat Lindblom B, Nordmann JP, Sellem E et al (2006) A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 84(7):74–83PubMed Lindblom B, Nordmann JP, Sellem E et al (2006) A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 84(7):74–83PubMed
13.
Zurück zum Zitat Tsai JC (2009) A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 116:S30–S36PubMedCrossRef Tsai JC (2009) A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 116:S30–S36PubMedCrossRef
15.
Zurück zum Zitat Stillitano IG, Lima MG, Ribeiro MP, Cabral J, Brandt CT (2005) Economic impact of eyedrop cost in glaucoma treatment. Arq Bras Oftalmol 68(1):79–84PubMedCrossRef Stillitano IG, Lima MG, Ribeiro MP, Cabral J, Brandt CT (2005) Economic impact of eyedrop cost in glaucoma treatment. Arq Bras Oftalmol 68(1):79–84PubMedCrossRef
16.
Zurück zum Zitat Ikeda H, Tsukamoto H, Sawa A, Sugimoto A, Mishima H, Kihira K (2005) Comparison of annual cost between Brand and generic ocular beta-adrenergic blockers. Yakugaku Zasshi 125(5):463–467PubMedCrossRef Ikeda H, Tsukamoto H, Sawa A, Sugimoto A, Mishima H, Kihira K (2005) Comparison of annual cost between Brand and generic ocular beta-adrenergic blockers. Yakugaku Zasshi 125(5):463–467PubMedCrossRef
17.
Zurück zum Zitat Fiscella RG, Geller JL, Gryz LL, Wilensky J, Viana M (1999) Cost considerations of medical therapy for glaucoma. Am J Ophthalmol 128(4):426–433PubMedCrossRef Fiscella RG, Geller JL, Gryz LL, Wilensky J, Viana M (1999) Cost considerations of medical therapy for glaucoma. Am J Ophthalmol 128(4):426–433PubMedCrossRef
18.
Zurück zum Zitat Fiscella RG, Green A, Patuszynski DH, Wilensky J (2003) Medical therapy cost considerations for glaucoma. Am J Ophthalmol 136(1):18–25PubMedCrossRef Fiscella RG, Green A, Patuszynski DH, Wilensky J (2003) Medical therapy cost considerations for glaucoma. Am J Ophthalmol 136(1):18–25PubMedCrossRef
19.
Zurück zum Zitat Gao Y, Wu L, Li A (2007) Daily cost of glaucoma medications in China. J Glaucoma 16(7):594–597PubMedCrossRef Gao Y, Wu L, Li A (2007) Daily cost of glaucoma medications in China. J Glaucoma 16(7):594–597PubMedCrossRef
20.
Zurück zum Zitat Rylander NR, Vold SD (2008) Cost analysis of glaucoma medications. Am J Ophthalmol 145(1):106–113PubMedCrossRef Rylander NR, Vold SD (2008) Cost analysis of glaucoma medications. Am J Ophthalmol 145(1):106–113PubMedCrossRef
23.
Zurück zum Zitat Omoti AE, Edema OT, Akpe BA, Musa P (2010) Cost analysis of medical versus surgical management of glaucoma in Nigeria. J Ophthalmic Vis Res 5(4):232–239PubMedCentralPubMed Omoti AE, Edema OT, Akpe BA, Musa P (2010) Cost analysis of medical versus surgical management of glaucoma in Nigeria. J Ophthalmic Vis Res 5(4):232–239PubMedCentralPubMed
24.
Zurück zum Zitat Frenkel RE, Frenkel M, Toler A (2007) Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension. BMC Ophthalmol 27:7–16 Frenkel RE, Frenkel M, Toler A (2007) Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension. BMC Ophthalmol 27:7–16
Metadaten
Titel
Topical glaucoma therapy cost in Mexico
verfasst von
Gabriel Lazcano-Gomez
Alejandra Hernandez-Oteyza
María José Iriarte-Barbosa
Carlos Hernandez-Garciadiego
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 2/2014
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-013-9823-6

Weitere Artikel der Ausgabe 2/2014

International Ophthalmology 2/2014 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.